**Abstract**

**Objective:** The UCSD Performance-Based Skills Assessment (UPSA) has been extensively utilized in patients with schizophrenia and bipolar disorder to measure functional capacity. This *post-hoc* analysis of NCT01564862 reports the psychometric properties of the UPSA in patients with major depressive disorder (MDD) in an outpatient clinical trial setting and determines clinically relevant treatment response (MCID).

**Methods:** Patients (18--65 years, Montgomery-Åsberg Depression Rating Scale \[MADRS\] ≥26) with self-reported cognitive dysfunction were enrolled in an 8-week, double-blind, placebo-controlled study. Clinical outcomes included the Digit Symbol Substitution Test (DSST) -- number of correct symbols, Clinical Global Impression Improvement (CGI-I), Working-Limitation-Questionnaire (WLQ), the patient-reported Perceived Deficits Questionnaire (PDQ), the Working Limitation Questionnaire (WLQ), MADRS, and UPSA. Construct validity was examined via baseline correlation analyses of the UPSA Composite Score (\"UPSA,\" comprising the UPSA and UPSA-B in English- and non-English-speaking patients, respectively) and clinical outcomes. Anchor-based (CGI-I ≤2) and distribution-based (one-half SD) analysis methods were used to establish a responder definition.

**Results:** Mean UPSA score at baseline was 77.8 (SD=12.88). Significant baseline correlations (*p*\<0.05) were observed between the UPSA and duration of current major depressive episode (MDE) (r=0.10), age (r=-0.13), education (r=0.29), DSST (r=0.36), and WLQ (r=-0.17), but not MADRS or PDQ. MADRS was only correlated (*p*\<0.05) with duration of the current MDE (r=0.13) and the PDQ (r=0.32). The anchor-based approach resulted in an estimate of a 6.7-point improvement for a responder definition on the UPSA, which was supported by the distribution-based approach (one-half SD = +6.44).

**Conclusion:** The UPSA was correlated with cognitive performance (DSST) and workplace productivity (WLQ) but not mood (MADRS) or subjective cognitive functioning (PDQ), supporting the construct validity of the UPSA for functional capacity in patients with MDD independent of mood symptoms. Anchor-based and distributional analyses suggest a ∼7-point improvement in UPSA as a responder definition for treatment response.
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